I think one of the things to watch is that you know we're seeing more M&A activity now and there were certainly examples in Richard's slides of some of the large M&A values that are being assigned to biotech companies that are being acquired and certainly more of them are considering the acquisition...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
